ClinicalTrials.gg
CompletedNCT06775730Updated May 4, 2025

A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

A Phase 1 interventional study of Ensitrelvir in Healthy Adult Female Participants, sponsored by Shionogi. Completed at 1 site in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by Shionogi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The purpose of this study is to examine the potential for drug-drug interactions.

02

Conditions studied

  • Healthy Adult Female Participants
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) within the range of ≥18.5 to ≤30.0 kilograms (kg)/square meter (m\^2) at the screening.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and either of the following conditions applies:

    • Is a woman of (WOCBP), having not received any oral for at least 28 days prior to the first dose of study intervention, and using a contraceptive method that is highly effective during the treatment period and for at least 14 days after the last dose of study intervention.
    • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention.

Key Exclusion Criteria:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
  • Presence (suspected) or history of having breast cancer, endometrial cancer, or cervical cancer.
  • Presence of unexplained genital bleeding.
  • Participants who have taken injectable or implantable contraceptives, hormonal intrauterine devices, intrauterine hormone-releasing system within 12 months prior to the first dose of study intervention or hormonal contraceptives (intravaginal or transdermal) for 3 months prior to the first dose of study intervention.
  • Participants who are otherwise considered ineligible for the study by the investigator for any other reason.

NOTE: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Ensitrelvir

    Participants will receive multiple oral doses of a combined oral contraceptive (COC) (EE and DRSP) once daily for 24 days (Days 1 to 24) (in the fasted state on Days 18 to 24) in the morning. Participants will also receive ensitrelvir high dose on Day 20 and multiple oral doses of ensitrelvir low dose once daily on Days 21 to 24 in the fasted state.

    Drug: Ensitrelvir

Interventions

  • Ensitrelvir will be administered per schedule specified in the arm description.

    Also known as: S-217622

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol (EE)

    Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24

  2. Cmax of Drospirenone (DRSP)

    Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24

  3. Time to Reach Cmax (Tmax) of EE

    Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24

  4. Tmax of DRSP

    Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24

  5. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC0-τ) of EE

    Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24

  6. AUC0-τ of DRSP

    Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Day 1 up to Day 32

  2. Cmax of Ensitrelvir

    Time frame: Predose and up to 24 hours postdose on Days 20 and 24

  3. Tmax of Ensitrelvir

    Time frame: Predose and up to 24 hours postdose on Days 20 and 24

  4. AUC0-τ of Ensitrelvir

    Time frame: Predose and up to 24 hours postdose on Days 20 and 24

07

Study locations

1 site
  • Early Phase Clinical Unit Los Angeles
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Apr 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 15, 2025
StartActual
Dec 30, 2024
Primary completionActual
Apr 3, 2025
CompletionActual
Apr 3, 2025
Last update
May 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06775730
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Dec 30, 2024
Primary completion
Apr 3, 2025
Completion
Apr 3, 2025
Last update
May 4, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensitrelvir

Start the discussion